Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA (Companion Faculty Lecture)

<p class="MsoNormal">Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics:</p> <ul> <li>All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00)</li> <li>Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21)</li> <li>First- and second-generation IDH inhibitors for AML (17:40)</li> <li>Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59)</li> <li>Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42)</li> <li>Novel combination approaches with menin inhibitors for AML (29:11)</li> </ul> <p class="MsoNormal"><a href= "http://m.researchtopractice.com/OncologyToday25/PostASCOEHAAML/Presentation"> CME information and select publications</a></p>